ClinicalTrials.gg
Active, not recruitingNCT05230459Updated Aug 26, 2026

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

A Phase 1/2 interventional study of AB-1003 dose level 1 and AB-1003 dose level 2 in Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2 and LGMD2I, sponsored by AskBio Inc. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by AskBio Inc (part of Bayer) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.

Enrollment
10th of 17
9 · median 11
Started
2023
with 2 others
Phase 1/2
5 of 30
none open now
Registered
21st of 30
by date
Lead sponsor
1 of 30
AskBio Inc

Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 10th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2023, is one of 5 in phase 1/2, and was the 21st registered.

Muscular Dystrophies, Limb-Girdle

47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.

Browse Muscular Dystrophies, Limb-Girdle studies →

Open to participants now

3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)

03

Conditions studied

  • Limb Girdle Muscular Dystrophy
  • Limb-Girdle Muscular Dystrophy Type 2
  • LGMD2I
  • Muscular Dystrophy
  • LGMD2
  • LGMD
  • FKRP
  • FKRP Mutation
  • Fukutin Related Protein

Keywords

  • gene therapy
  • LGMD2I
  • LGMD2I/R9
  • gene augmentation therapy
  • FKRP
  • fukutin related protein
  • FKRP mutation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects aged 18 and 65 years with clinical diagnosis of LGMD2I/R9 and confirmation of FKRP gene mutation.
  2. Ability to walk/run 10 meters in \<30 seconds.
  3. Able to understand and comply with all study procedures.
  4. Sexually active females of and female and male partners of male subjects receiving study intervention must use a barrier method of for the first 6 months after dosing.

Exclusion criteria

Exclusion Criteria:

  1. Significant cardiomyopathy as defined by echocardiogram ( \<40%), evidence of conduction defect (increased PR and RR intervals, left bundle branch block and >480m/sec), Class 3 or 4 heart failure, or MRI gadolinium enhancement evidence of myocardial fibrosis.
  2. to MRI or to contrast dyes, shellfish or iodine.
  3. Implanted spinal rods, cardiac pacemaker or other implantation that would distort cardiac MRI images.
  4. History of active, ongoing chronic liver disease (e.g. hepatitis, -related liver disease, hemochromatosis, steatosis, etc.) or abnormal liver function tests (abnormal GGT and/or abnormal total/direct > [ULN] and/or elevated and ALT >2 ULN).
  5. Abnormal renal function ( \<60 ml/min, using the Modification of Diet in Renal Disease equation).
  6. Any life-threatening disease, including malignant neoplasms and medical history or malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).
  7. In the opinion of the investigator, a pre-existing medical condition that predisposes the subject to risks that outweighs the potential benefits.
  8. Requirement for daytime ventilatory support.
  9. Change in glucocorticosteroid treatment within 3 months prior to screening visit.
  10. Exposure to another drug within 3 months prior to study treatment or any previous treatment with gene therapy.
  11. Ongoing participation in any other therapeutic clinical trial.
  12. Neutralizing antibody titer to AAV9 >1:5.
  13. Female subjects who are pregnant, plan to become pregnant in the next 12 months, or breastfeeding.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    AB-1003 Cohort 1

    Genetic: AB-1003 dose level 1

  • Experimental
    AB-1003 Cohort 2

    Genetic: AB-1003 dose level 2

  • Placebo comparator
    Placebo (Cohorts 1 and 2)

    Drug: Placebo

Interventions

  • GeneticAB-1003 dose level 1

    Single intravenous infusion of AB-1003 gene therapy at dose level 1

  • GeneticAB-1003 dose level 2

    Single intravenous infusion of AB-1003 gene therapy at dose level 2

  • DrugPlacebo

    Single intravenous infusion of Placebo

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Treatment Emergent Adverse Events, Serious Adverse Events, Dose Limiting Toxicity

    Time frame: 0-52 weeks

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Dec 2028, 67 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 9, 2022
StartActual
May 15, 2023
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2032
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05230459
Lead sponsor
AskBio Inc
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
May 15, 2023
Primary completion
Dec 2028 (estimated)
Completion
Dec 2032 (estimated)
Last update
Aug 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion